mRNA-LNP vaccine providing antigen and co-stimulation in the tumor microenvironment enhances CAR T cell function (CART-Vac)
{{output}}
Despite advances in multimodal therapies, outcomes for pediatric patients with relapsed or refractory cancers remain poor. Chimeric antigen receptor (CAR) T cell therapy has demonstrated limited efficacy in solid tumors due to the immunosuppressive tumor micro... ...
